Clinical Report: Mapping the Genome in 4D

Overview

A comprehensive analysis of the human 4D nucleome reveals how the three-dimensional organization of the genome varies across different cell types and states, influencing gene regulation and DNA replication. The study identifies over 140,000 chromatin loops and provides insights into the utility of various genome architecture assays.

Background

Understanding the spatial organization of the genome is crucial for elucidating gene regulation mechanisms and the impact of genetic variants on disease. The 4D nucleome project integrates multiple high-throughput assays to map chromatin interactions, offering a detailed view of genome architecture. This knowledge is essential for advancing diagnostic approaches in genetics and personalized medicine.

Data Highlights

No numerical data available.

Key Findings

Clinical Implications

Detail specific examples of how findings can influence clinical practices regarding genetic disorders.

Conclusion

This study significantly advances our understanding of the 4D nucleome, highlighting its relevance in gene regulation and potential implications for genetic diagnostics.

References

1. NIH 4D Nucleome consortium, Nature, 2026 -- An integrated view of the structure and function of the human 4D nucleome
2. The Pathologist, 2026 -- From Genome to Multi-ome
3. The Analytical Scientist, 2026 -- Towards a Unified Picture of Chromatin Biology
4. Acta Neuropathologica, 2020 -- Molecular Distinctions Between Atypical Teratoid/Rhabdoid Tumors with SMARCA4 Mutations and SMARCB1-Deficient Variants
5. Genome Medicine -- Combining chromosome conformation capture and exome sequencing for simultaneous detection of structural and single-nucleotide variants
6. the analytical scientist — Mapping Molecular Discordance in the Brain 
7. An integrated view of the structure and function of the human 4D nucleome | Nature
8. Combining chromosome conformation capture and exome sequencing for simultaneous detection of structural and single-nucleotide variants | Genome Medicine | Full Text
9. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - PMC